Talk
Coenzyme Q10 as a treatment for mitochondrial dysfunction

Bio
Dr. Iain P. Hargreaves is a Reader in Clinical Biochemistry at Liverpool John Moores University and an Hon. Associate Professor in Biochemistry at the University College of London. His research interests focus on mitochondrial dysfunction and oxidative stress in metabolic diseases. At present, he is investigating the causes and evidence of secondary mitochondrial dysfunction in lysosomal storage disease.

Talk
Title: Coenzyme Q10 as a treatment for mitochondrial dysfunction

Bio
Dr. Iain P. Hargreaves is a Reader in Clinical Biochemistry at Liverpool John Moores University and an Hon. Associate Professor in Biochemistry at the University College of London. His research interests focus on mitochondrial dysfunction and oxidative stress in metabolic diseases. At present, he is investigating the causes and evidence of secondary mitochondrial dysfunction in lysosomal storage disease.

Talk
Title: Biogenesis of complex IV

Bio
Dr. Gavin McStay is a senior lecturer in biotechnology at Liverpool John Moores University. He is interested in understanding quality control mechanisms and signal transduction pathways activated by mitochondrial stress and disease. His research examines the structure–function relationships of oxidative phosphorylation complexes, particularly Complex I and Complex IV, and how defects in mitochondrial architecture drive metabolic dysfunction and pathology. He combines biochemical, cellular, and molecular approaches to investigate mitochondrial signalling and energy metabolism. Gavin also directs Biomed News, a free platform for biomedical research literature discovery that currently has a particular focus on mitochondria.

Talk
Title: Mitochondrial Redox Signaling in Skeletal Muscle Adaptation and Ageing.

Bio
Dr. Robert A. Heaton is a Lecturer in Biochemistry at Liverpool John Moores University whose research focuses on redox biology and mitochondrial signalling in human health and disease. His early work investigated reactive oxygen species as signalling molecules regulating skeletal muscle adaptation to exercise and the mechanisms underlying age-related muscle decline, with particular emphasis on mitochondrial ROS production and peroxiredoxin-mediated redox signalling. His current research expands these principles into translational models of human disease, including women’s reproductive health, where he studies how mitochondrial and lysosomal redox imbalance contributes to disorders such as adenomyosis and endometriosis. Across these areas, his work aims to define how redox signalling governs cellular adaptation, recovery, and maladaptation under physiological and pathological stress.

Talk
Title: Mitochondria the lynchpin in skeletal muscle health & disease

Bio
Dr. Adam Lightfoot is Senior Lecturer in Cell & Molecular Physiology at Manchester Metropolitan University. Adam holds a PhD in Pathophysiology from the University of Liverpool (2011). He undertook postdoctoral training in the study of Idiopathic Inflammatory Myopathies and was appointed Lecturer at Manchester Met in 2016. Interspersed with an appointment in obesity medicine at Novo Nordisk in 2021, Adam currently leads a research group dedicated to the mechanistic study of muscle wasting and weakness. His research interests span the role of mitochondria and redox homeostasis in the pathogenesis of rare neuromuscular diseases (myositis), age-related loss of muscle mass and function, and obesity. With more recent focus on the development of functional human pre-clinical models of muscle/myopathies, as a platform for mechanistic interrogation.